Close Menu

cytogenetics

This article was originally posted on Feb. 1

By the end of next year, all of the large array vendors could have US Food and Drug Administration-cleared products on the market for postnatal constitutional cytogenetics.

Illumina's acquisition of BlueGnome has provided a boost for its array business.

SAN FRANCISCO — Illumina will not be the only array vendor submitting a cytogenetics-focused array to the US Food and Drug Administration for clearance this quarter.

Illumina CEO Jay Flatley provided an update on the company's array business at the JP Morgan Global Healthcare Conference in San Francisco this week.

Things are looking up for CombiMatrix. The Irvine, Calif.-based molecular diagnostics firm this week reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full year 2012, respectively.

The global adoption of microarrays for the detection of genetic abnormalities has continued into the new year, with Chinese life sciences company CapitalBio announcing recently the introduction of chromosomal microarray analysis services via its medical testing laboratories.

This article was originally posted on Dec. 6.
Several studies published last week in the New England Journal of Medicine underscore the rapidly shifting landscape for genomic tools in the diagnostic setting.

"Explosive" and "enormous" are the words Simon Sheng uses to describe the market for microarray technology in China. As general manager for Affymetrix's office in the country, Sheng said he has hired eight sales and marketing personnel this year and hopes to add more soon.

Yongguo Yu is what the Chinese refer to as a "sea turtle," a professional who has received his education or pursued a career abroad, only to put any skills acquired to use upon return to his native country.

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.